Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. (HOWL) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · HOWL · as of Sep 30, 2025
Ownership Breakdown
62
Institutional Holders
▼ 4 vs Q2
$41.57M
Total Inst. Value
▲ $17.23M vs Q2
48.60M
Shares Outstanding
freeFloat 84.85%
21.11M
13F Shares Held
▼ 1.23M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
HOWL largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 6.68M | 14.85% | 14.85% | $13.16B | Nov 14, 2025 | — held |
MPM ASSET MANAGEMENT LLC pharmaceutical preparations | 4.31M | 9.58% | 9.58% | $8.49B | Nov 14, 2025 | — held |
BIOIMPACT CAPITAL LLC pharmaceutical preparations | 2.41M | 5.36% | 5.36% | $4.75B | Nov 14, 2025 | — held |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 1.83M | 4.07% | 4.07% | $3.61B | Feb 3, 2026 | ▼ 298.7K |
VANGUARD GROUP INC pharmaceutical preparations | 1.41M | 3.13% | 3.13% | $2.77B | Nov 7, 2025 | ▲ 109.8K |
SPHERA FUNDS MANAGEMENT LTD. pharmaceutical preparations | 626.8K | 1.39% | 1.39% | $1.23B | Nov 14, 2025 | — held |
DC FUNDS, LP pharmaceutical preparations | 589.1K | 1.31% | 1.31% | $1.16B | Nov 10, 2025 | — held |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 456.0K | 1.01% | 1.01% | $898.32M | Nov 13, 2025 | ▲ 139.7K |
PFM HEALTH SCIENCES, LP pharmaceutical preparations | 401.1K | 89.17% | 89.17% | $790.19M | Nov 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 330.8K | 73.54% | 73.54% | $651.83M | Nov 12, 2025 | ▲ 2.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
9
Increased
+293.5K shares5
New Positions
first time holders16
Decreased
−1.41M shares0
Sold Out
fully exitedNet shares change (top 50)
1.12M
+293.5K / −1.41M
Net new holders
-2
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
HOWL insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
34
Sell transactions
0.00
Buy/Sell ratio
$2M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
EVNIN LUKE director | Jun 4, 2026 | Sale | 20,072 | $0.44 | $8.8K | 462.7K | Form 4 ↗ |
EVNIN LUKE director | Jun 5, 2026 | Sale | 24,946 | $0.40 | $10.0K | 437.8K | Form 4 ↗ |
EVNIN LUKE director | Jun 8, 2026 | Sale | 60,547 | $0.40 | $24.2K | 377.2K | Form 4 ↗ |
EVNIN LUKE director | Jun 1, 2026 | Sale | 80,459 | $0.47 | $37.8K | 542.1K | Form 4 ↗ |
EVNIN LUKE director | Jun 2, 2026 | Sale | 29,595 | $0.45 | $13.3K | 512.5K | Form 4 ↗ |
EVNIN LUKE director | Jun 3, 2026 | Sale | 29,749 | $0.42 | $12.5K | 482.8K | Form 4 ↗ |
EVNIN LUKE director | May 27, 2026 | Sale | 80,852 | $0.48 | $38.8K | 682.8K | Form 4 ↗ |
EVNIN LUKE director | May 28, 2026 | Sale | 27,698 | $0.46 | $12.7K | 655.1K | Form 4 ↗ |
EVNIN LUKE director | May 29, 2026 | Sale | 32,556 | $0.45 | $14.7K | 622.6K | Form 4 ↗ |
EVNIN LUKE director | May 21, 2026 | Sale | 36,387 | $0.42 | $15.3K | 919.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Werewolf Therapeutics, Inc. (HOWL) is primarily owned by institutional investors, who hold approximately 43.4% of total shares outstanding. Company insiders own approximately 15.15%, while retail and public investors account for the remaining 41.41%.
The largest institutional shareholder of Werewolf Therapeutics, Inc. is RA CAPITAL MANAGEMENT, L.P., holding approximately 6.68 million shares — equal to 14.85% of outstanding shares — as of September 30, 2025.
A total of 62 institutional investors currently hold HOWL stock, with a combined institutional value of approximately $41,572,612 as of the most recent 13F filing period.
Frequently asked questions
HOWL ownershipWerewolf Therapeutics, Inc. (HOWL) is primarily owned by institutional investors, who hold approximately 43.4% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 14.85% stake. Company insiders hold 15.15%. Data sourced from SEC Form 13F as of September 30, 2025.